AI and Drug Development: IP Implications for Protecting AI Discoveries

AI and Drug Development: IP Implications for Protecting AI Discoveries

View Session Speakers

As with many industries, Artificial intelligence (AI) enabled solutions are revolutionizing every stage of the drug development process to accelerate it and improve its efficiency. As biopharmaceutical companies increasingly rely on AI, there is a real possibility that a drug substance, drug product, or a drug formulation soon will be invented by AI. If and when that happens, who owns the intellectual property for those inventions?

Patent Offices around the world, including the United States Patent and Trademark Office, have determined that an AI cannot be listed as an inventor. If AI-created inventions cannot be patented, will the biopharmaceutical companies be interested in pursuing inventions using AI to develop drug products?

Our panel will tackle these and other complicated and thorny legal issues presented by the use of AI in the drug development process.

Materials*

Protecting Artificial Intelligence Inventions in Drug Development

CAFC ‘Unambiguously’ Backs USPTO in AI as Inventor Fight

* A Note on Materials: We apply for MCLE, which requires substantive writing on the topic covered. The materials provided below, often published by IPWatchdog.com authors and contributors, relate to the topic but are not intended to pigeon-hole guest speakers in any way. They are hopefully informative, and the articles we select have to date always been sufficient to satisfy MCLE authorities.